Moderna And Merck Say Their mRNA Cancer Vaccine Cut Death, Recurrence By 42%

Moderna and Merck said a Phase 3 trial found that their personalized mRNA cancer vaccine, intismeran, when given with Keytruda, reduced the risk of melanoma recurrence or death by 42% over two years compared with Keytruda and placebo. The companies reported the findings for patients whose melanoma had been surgically removed, a group treated after surgery to lower the risk that cancer returns.

According to the companies’ announcement, 82% of patients who received intismeran plus Keytruda were alive without recurrence at two years, compared with 70% in the Keytruda-and-placebo group. The reported 42% figure describes a relative reduction in the risk of recurrence or death; it does not mean that 42% more patients were cured. The supplied report does not provide the trial’s participant count or confidence intervals.

The companies also reported a 38% reduction in the risk of distant metastasis or death with the vaccine combination. At the reported assessment, 88.5% of the combination group were alive without distant metastasis, compared with 80% of those receiving Keytruda and placebo. Recurrence-free survival measures time without the cancer returning, while distant metastasis-free survival tracks time without cancer returning at a distant site; both measures also count death as an event in the reported risk comparisons.

Intismeran, also known as mRNA-4157, is designed for each patient. Researchers identify mutations in an individual’s tumor by comparing its genetic sequence with healthy cells, then use synthetic mRNA encoding selected cancer-specific mutations to prompt an immune response. In the trial, it was tested alongside Keytruda (pembrolizumab), Merck’s immunotherapy, against Keytruda plus placebo.

A Post-Surgery Option Under Study

The findings address a key problem in melanoma care: even after a tumor has been removed, cancer can return or spread. The reported difference in two-year outcomes suggests that a personalized vaccine might add benefit to an existing immunotherapy regimen in this post-surgery, or adjuvant, setting. If confirmed through full data review and follow-up, the approach could expand options for patients at risk of recurrence.

The results are not evidence that the vaccine prevents every recurrence, nor do they establish how long any benefit lasts. The reported percentages show that some patients in both groups remained alive without recurrence, and the risk reduction is a comparison between treatment groups. Patients should not interpret the announcement as a change in their own care; treatment decisions depend on individual circumstances and qualified clinicians.

How the Vaccine Was Tested

The Phase 3 comparison tested intismeran plus Keytruda against Keytruda plus placebo among people with surgically removed melanoma. That design helps assess whether adding the personalized vaccine improves outcomes beyond the immunotherapy alone. The measures reported are survival outcomes without recurrence or distant spread, rather than a claim that all disease was eliminated.

The supplied report says a prior five-year Phase 2 trial showed a 49% reduction in recurrence or death risk and a 59% reduction in distant metastasis or death risk. Those figures come from a different study and follow-up period, so they should not be directly treated as the same measurement as the new Phase 3 two-year results. The current announcement reports a smaller effect on both measures than those earlier Phase 2 estimates.

“The trial “is the first Phase 3 study to demonstrate a clinically meaningful improvement in RFS and DMFS over standard-of-care KEYTRUDA in patients with resected melanoma, setting a new benchmark in the adjuvant setting and representing one of the most significant advances in melanoma treatment since the advent of immunotherapy.””

— Dean Li, president of Merck Research Laboratories

Full Trial Data Still Needed

The figures available here come from a company announcement and a report summarizing it. The supplied material does not include the full study publication, participant numbers, detailed statistical results, adverse-event data, or a complete account of the trial population. Those details are needed to evaluate the size, reliability, and safety profile of the reported benefit.

It is also not clear from the source material when complete results will be published or whether regulators have reviewed the Phase 3 findings. The two-year figures do not establish whether the difference will persist with longer follow-up. The companies’ results describe outcomes for the trial groups and cannot by themselves predict an individual patient’s response.

Publication and Longer Follow-Up

The next steps are publication of the full Phase 3 results and continued follow-up of participants to measure whether the reported differences last. Those data would allow clinicians and researchers to examine patient characteristics, statistical uncertainty, side effects, and outcomes over a longer period. Any regulatory decisions or changes to treatment guidance would depend on further review; the source material does not specify a decision date.

Key Questions

What did the companies report?

Moderna and Merck said that, after two years, intismeran plus Keytruda was associated with a 42% lower risk of recurrence or death than Keytruda plus placebo in the Phase 3 trial. The report also gave a 38% lower risk of distant metastasis or death.

Does a 42% risk reduction mean 42% more patients were cured?

No. The reported 42% is a relative reduction in risk compared with the control group. At two years, the companies said 82% of the vaccine-combination group and 70% of the Keytruda-and-placebo group were alive without recurrence.

What is intismeran?

Intismeran, also called mRNA-4157, is a personalized mRNA vaccine designed using mutations identified in a patient’s tumor. It was tested with pembrolizumab, sold as Keytruda.

Is the vaccine approved for routine melanoma treatment?

The supplied source material does not say that the vaccine has received regulatory approval for this use. The reported findings are trial results; publication and regulatory status are not specified.

What remains unknown about the results?

The supplied material does not include full trial data, participant numbers, detailed safety results, or longer-term outcomes. Those details are needed to judge the findings beyond the companies’ reported two-year comparisons.

Source: hn